11 assets in Ocular Melanoma

Therapeutic assets addressing Ocular Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Ocular Melanoma	University of Michigan Rogel Cancer Center	P2	BB (65)
Nivolumab Ocular Melanoma	University of Michigan Rogel Cancer Center	P2	B (62)
Bel-Sar Ocular Melanoma	Aura Biosciences	P3	B (60)
Cyclophosphamide Ocular Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (60)
Pembrolizumab Ocular Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (60)
Fludarabine Ocular Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (59)
Darovasertib Ocular Melanoma	St Vincent's Hospital, Sydney	P2	B (57)
Olaparib Ocular Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (53)
Roginolisib Ocular Melanoma	iOnctura	P2	CCC (53)
Iov-3001 Ocular Melanoma	Iovance Biotherapeutics, Inc.	P1/2	CCC (48)
Tbio-4101 Ocular Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (46)